Novocure Ltd Ord Sh (NVCR)

$13.32 -0.34 (-2.49%)
Market Cap 1.49B
Revenue (ttm) 605.22M
Net Income (ttm) -168.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.86%
Debt to Equity Ratio 0.57
Volume 2,087,000
Avg Vol 1,615,874
Day's Range N/A - N/A
Shares Out 111.98M
Stochastic %K 80%
Beta 0.83
Analysts Strong Sell
Price Target $25.36

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic ca...

Industry: Medical Devices
Sector: Healthcare
Address:
Neuhofstrasse 21, Baar, Switzerland
TommBa
TommBa Dec. 11 at 10:30 PM
$NWBO will it seems someone is worried about what is coming. Look who shows up for me on Google as a sponsored result when I searched for dcvax. Note: I am based in Spain at the moment, which is why $NVCR is showing .es
0 · Reply
scotofool
scotofool Dec. 11 at 4:41 PM
$NVCR @RudeYak wanker, price ridings markets, wait bottoms, looky history. trashy device, pisspoor leaders, falsified datas, proper cock-up. target 7
1 · Reply
RudeYak
RudeYak Dec. 11 at 4:13 PM
$NVCR since post stock's up 16%. This guy's an angry elf. We need some positive news and let this fly back to $32+
2 · Reply
scotofool
scotofool Dec. 11 at 3:18 PM
$NVCR ignore pumpy-dumpy,$NVCR proper trash leaders CEO, will crash. target 7
0 · Reply
kwcurtis
kwcurtis Dec. 11 at 3:02 PM
$NVCR feeling pretty good after an 11.03 entry…
0 · Reply
juiceHunter
juiceHunter Dec. 11 at 7:17 AM
$NVCR 🤷🏻‍♂️🤭
0 · Reply
PickAlpha
PickAlpha Dec. 9 at 2:15 AM
PickAlpha Evening Insights | 2025-12-08 - Three Trades For Tomorrow 1/3 Long $NVCR — At NVCR’s Nasdaq resumption (scheduled 07:55 ET Dec 9), if the opening trade is at least 8% below the last pre-halt close, go long NVCR within the first 2 minutes. Target a retracement of half the gap (4% vs the last close) or exit by 11:00 ET… The Nasdaq resumption schedule gives precise premarket restart times, creating defined liquidity windows. Stocks coming off halts frequently overshoot on the opening print before mean-reverting intraday. Using NVCR, a volatile name, a rules-based buy on a large gap-down versus the last pre-halt close exploits potential order-imbalance dislocations while controlling risk with explicit time and percentage limits. Trade credibility: actionability 8.0 | timeliness 8.0 | clarity 8.0
0 · Reply
buylowandwait
buylowandwait Dec. 5 at 11:27 PM
$NVCR $KOD The biggest gain for me this year is KOD, which I bought at 2.8 and it is well above 20. It is 800% gain in a little over a year. As it is not in my top 5 positions, the portofolio impact is relatively small. Looking into 2026, I have AI, BIO, adTech & Fintech, and commodity exposure. Both AI and bio are doing well in 2025, but which stock has the biggest potential gain heading into 2026? Strangely enough, despite huge setback, I am still very hopeful for NVCR to come back in 2026. If the company execute well, and stars line up, we could have 800% gain for NVCR in a couple of years.
1 · Reply
GeneralLion
GeneralLion Dec. 5 at 6:00 PM
$NVCR https://www.keckmedicine.org/physician-hub/for-glioblastoma-patients-with-bulky-biopsy-only-tumors-could-this-become-a-new-treatment-option/
1 · Reply
scotofool
scotofool Dec. 5 at 4:54 PM
$NVCR @Do_Your_Research tosspots running the place iz reason mate
0 · Reply
Latest News on NVCR
Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Dec 1, 2025, 7:00 AM EST - 12 days ago

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 17 days ago

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

Nov 12, 2025, 10:00 AM EST - 4 weeks ago

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

DHR

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Nov 12, 2025, 7:00 AM EST - 4 weeks ago

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 3:16 PM EDT - 6 weeks ago

NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

Novocure Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 6 weeks ago

Novocure Reports Third Quarter 2025 Financial Results

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Oct 17, 2025, 7:55 AM EDT - 2 months ago

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 15, 2025, 7:00 AM EDT - 2 months ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure to Report Third Quarter 2025 Financial Results

Oct 1, 2025, 7:00 AM EDT - 2 months ago

Novocure to Report Third Quarter 2025 Financial Results

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 29, 2025, 4:30 PM EDT - 2 months ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 15, 2025, 7:00 AM EDT - 3 months ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 5:53 PM EDT - 3 months ago

NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

Aug 29, 2025, 4:26 AM EDT - 3 months ago

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

LLY

Novocure Announces Upcoming Investor Events

Aug 28, 2025, 7:00 AM EDT - 3 months ago

Novocure Announces Upcoming Investor Events

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 25, 2025, 7:00 AM EDT - 3 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Aug 20, 2025, 7:00 AM EDT - 4 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

NovoCure's Wearable Oncology Edge And Compelling Valuation

Jul 30, 2025, 12:47 AM EDT - 4 months ago

NovoCure's Wearable Oncology Edge And Compelling Valuation

Top 3 Health Care Stocks That May Explode In July

Jul 28, 2025, 6:52 AM EDT - 4 months ago

Top 3 Health Care Stocks That May Explode In July

HCA MOH

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

Jul 25, 2025, 4:49 PM EDT - 5 months ago

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

NovoCure Q2 Revenue Jumps 6 Percent

Jul 24, 2025, 6:37 PM EDT - 5 months ago

NovoCure Q2 Revenue Jumps 6 Percent

Novocure: Steady Ahead of Key Milestones

Jul 24, 2025, 9:21 AM EDT - 5 months ago

Novocure: Steady Ahead of Key Milestones

Novocure Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 5 months ago

Novocure Reports Second Quarter 2025 Financial Results

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jul 1, 2025, 7:00 AM EDT - 5 months ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Novocure to Report Second Quarter 2025 Financial Results

Jun 30, 2025, 7:00 AM EDT - 5 months ago

Novocure to Report Second Quarter 2025 Financial Results

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Jun 2, 2025, 2:05 PM EDT - 6 months ago

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 7 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 8:00 AM EDT - 7 months ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

May 28, 2025, 6:57 AM EDT - 7 months ago

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

NovoCure: Loading Up On Growth Catalysts

May 24, 2025, 3:12 AM EDT - 7 months ago

NovoCure: Loading Up On Growth Catalysts

Why NovoCure Stock Skyrocketed This Week

Apr 25, 2025, 1:21 PM EDT - 8 months ago

Why NovoCure Stock Skyrocketed This Week

Why NovoCure Stock Leaped 4% Higher Today

Apr 24, 2025, 7:03 PM EDT - 8 months ago

Why NovoCure Stock Leaped 4% Higher Today

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

Apr 24, 2025, 12:39 PM EDT - 8 months ago

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 10:34 AM EDT - 8 months ago

NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript

NovoCure Surpasses Q1 Expectations

Apr 24, 2025, 9:25 AM EDT - 8 months ago

NovoCure Surpasses Q1 Expectations

Novocure Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 8 months ago

Novocure Reports First Quarter 2025 Financial Results

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 10:16 AM EDT - 8 months ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 22, 2025, 7:09 AM EDT - 8 months ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Why NovoCure Stock Was Withering on Wednesday

Apr 16, 2025, 3:43 PM EDT - 8 months ago

Why NovoCure Stock Was Withering on Wednesday

Novocure to Report First Quarter 2025 Financial Results

Apr 1, 2025, 7:00 AM EDT - 9 months ago

Novocure to Report First Quarter 2025 Financial Results

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why

Mar 4, 2025, 7:00 PM EST - 10 months ago

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 10 months ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

Feb 28, 2025, 1:10 PM EST - 10 months ago

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

Feb 28, 2025, 5:17 AM EST - 10 months ago

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

Feb 27, 2025, 9:09 AM EST - 10 months ago

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

NovoCure Q4 EPS Misses, Revenue Matches

Feb 27, 2025, 8:53 AM EST - 10 months ago

NovoCure Q4 EPS Misses, Revenue Matches

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 27, 2025, 7:00 AM EST - 10 months ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 22, 2025, 4:00 AM EST - 11 months ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 13, 2025, 7:00 AM EST - 11 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Why NovoCure Stock Was Winning Big This Week

Dec 6, 2024, 8:32 AM EST - 1 year ago

Why NovoCure Stock Was Winning Big This Week

TommBa
TommBa Dec. 11 at 10:30 PM
$NWBO will it seems someone is worried about what is coming. Look who shows up for me on Google as a sponsored result when I searched for dcvax. Note: I am based in Spain at the moment, which is why $NVCR is showing .es
0 · Reply
scotofool
scotofool Dec. 11 at 4:41 PM
$NVCR @RudeYak wanker, price ridings markets, wait bottoms, looky history. trashy device, pisspoor leaders, falsified datas, proper cock-up. target 7
1 · Reply
RudeYak
RudeYak Dec. 11 at 4:13 PM
$NVCR since post stock's up 16%. This guy's an angry elf. We need some positive news and let this fly back to $32+
2 · Reply
scotofool
scotofool Dec. 11 at 3:18 PM
$NVCR ignore pumpy-dumpy,$NVCR proper trash leaders CEO, will crash. target 7
0 · Reply
kwcurtis
kwcurtis Dec. 11 at 3:02 PM
$NVCR feeling pretty good after an 11.03 entry…
0 · Reply
juiceHunter
juiceHunter Dec. 11 at 7:17 AM
$NVCR 🤷🏻‍♂️🤭
0 · Reply
PickAlpha
PickAlpha Dec. 9 at 2:15 AM
PickAlpha Evening Insights | 2025-12-08 - Three Trades For Tomorrow 1/3 Long $NVCR — At NVCR’s Nasdaq resumption (scheduled 07:55 ET Dec 9), if the opening trade is at least 8% below the last pre-halt close, go long NVCR within the first 2 minutes. Target a retracement of half the gap (4% vs the last close) or exit by 11:00 ET… The Nasdaq resumption schedule gives precise premarket restart times, creating defined liquidity windows. Stocks coming off halts frequently overshoot on the opening print before mean-reverting intraday. Using NVCR, a volatile name, a rules-based buy on a large gap-down versus the last pre-halt close exploits potential order-imbalance dislocations while controlling risk with explicit time and percentage limits. Trade credibility: actionability 8.0 | timeliness 8.0 | clarity 8.0
0 · Reply
buylowandwait
buylowandwait Dec. 5 at 11:27 PM
$NVCR $KOD The biggest gain for me this year is KOD, which I bought at 2.8 and it is well above 20. It is 800% gain in a little over a year. As it is not in my top 5 positions, the portofolio impact is relatively small. Looking into 2026, I have AI, BIO, adTech & Fintech, and commodity exposure. Both AI and bio are doing well in 2025, but which stock has the biggest potential gain heading into 2026? Strangely enough, despite huge setback, I am still very hopeful for NVCR to come back in 2026. If the company execute well, and stars line up, we could have 800% gain for NVCR in a couple of years.
1 · Reply
GeneralLion
GeneralLion Dec. 5 at 6:00 PM
$NVCR https://www.keckmedicine.org/physician-hub/for-glioblastoma-patients-with-bulky-biopsy-only-tumors-could-this-become-a-new-treatment-option/
1 · Reply
scotofool
scotofool Dec. 5 at 4:54 PM
$NVCR @Do_Your_Research tosspots running the place iz reason mate
0 · Reply
scotofool
scotofool Dec. 5 at 4:51 PM
@kellysmith1 rubbish, wanker new ceo failure years. piss off fakey_pumper.$NVCR proper trash, target 7
0 · Reply
Do_Your_Research
Do_Your_Research Dec. 4 at 7:17 PM
$NVCR anybody know why they went for metastatic for panova 4 instead of locally advanced? They know that more time on treatment is needed to see results. Seems like it would have been easier to show a large benefit in locally advanced.
2 · Reply
kellysmith1
kellysmith1 Dec. 4 at 6:14 PM
$NVCR CEO who knows what he is doing. Very excited for the future!!
1 · Reply
kellysmith1
kellysmith1 Dec. 4 at 6:07 PM
$NVCR but all you can…this one will rock and roll the next few months!! Buy and hold!
0 · Reply
scotofool
scotofool Dec. 4 at 12:19 PM
$NVCR can yuz hear the wankers coming? saying new ceo to turn around this save that. bollocks. saying to 40 watch. no tis proper cock-up. board riggered doyly more same. $NVCR trash, target 7.
0 · Reply
BostonNorth
BostonNorth Dec. 3 at 11:10 PM
$NVCR 🔥🥊
0 · Reply
Kyle7776
Kyle7776 Dec. 3 at 5:45 PM
$NVCR if both trident and panova hit could we go back to 40+ ?
1 · Reply
sck2
sck2 Dec. 3 at 12:23 PM
$NVCR 🕵️‍♂️
0 · Reply
sck2
sck2 Dec. 3 at 12:01 PM
$NVCR 🕵️‍♂️
0 · Reply
sck2
sck2 Dec. 2 at 9:57 PM
$NVCR 🕵️‍♂️💪🐂
0 · Reply
joed88
joed88 Dec. 2 at 7:20 PM
$NVCR Main Points - Doyle's - Bednar's Chat: CEO and Management Transitions Novocure is shifting from a single-product company to a multi-indication platform active in 16 countries. The board appointed Frank Leonard CEO to reinforce execution toward 2026, without changing the company’s declared strategy or targets. Leonard brings years of experience, including product development, significant cost reductions, and strengthening commercial/international operations, which has driven double-digit GBM growth outside the US in 2024. The CEO change is described as “management optimization”—realignment of responsibilities, capital allocation, and team structures to increase the likelihood of achieving already stated goals for the coming years.
7 · Reply
kellysmith1
kellysmith1 Dec. 2 at 6:34 PM
$NVCR because they are idiots!!!
0 · Reply